Literature DB >> 2555388

Plasma pancreastatin-like immunoreactivity in various diseases.

K Tateishi1, A Funakoshi, H Wakasugi, H Iguchi, H Shinozaki, M Abe, S Funakoshi, H Tamamura, H Yajima, Y Matsuoka.   

Abstract

Plasma pancreastatin (PST)-like immunoreactivity in normal subjects and patients with various diseases was estimated by a RIA, using antiserum raised against a synthetic C-terminal peptide of human PST deduced from the sequence of human chromogranin-A. The mean level +/- SEM was 13.2 +/- 0.6 pmol/L in normal subjects, but was significantly higher in patients with chronic renal failure (526.7 +/- 48.5). An immunoreactive form corresponding to a human PST-like sequence [human chromogranin-A-(250-301)] and a larger form were detected by gel filtration of plasma from these patients, suggesting accumulation of the larger molecular form in these patients. A significant increase in PST-like immunoreactivity was also found in patients with liver cirrhosis (20.8 +/- 3.0 pmol/L), but not in patients with noninsulin-dependent diabetes mellitus, chronic pancreatitis, or pancreatic cancer. Elevated levels were found in 16 of the 21 patients with small cell lung carcinoma examined. High levels were also found in 3 of 11 patients with islet cell tumor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555388     DOI: 10.1210/jcem-69-6-1305

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Undegraded chromogranin A is present in serum and enters the endocytotic lysosomal pathway in kidney.

Authors:  R Weiler; H J Steiner; R Fischer-Colbrie; K W Schmid; H Winkler
Journal:  Histochemistry       Date:  1991

2.  Plasma pancreastatin responses after intrajejunal infusion of liquid meal in patients with chronic pancreatitis.

Authors:  A Funakoshi; K Tateishi; H Shinozaki; K Miyasaka; T Ito; H Wakasugi
Journal:  Dig Dis Sci       Date:  1990-06       Impact factor: 3.199

3.  Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression.

Authors:  L Jin; B W Scheithauer; W F Young; D H Davis; G G Klee; R V Lloyd
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

Review 4.  The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.

Authors:  Steven A Feldman; Lee E Eiden
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

5.  Immunohistochemical Localization of Chromostatin and Pancreastatin, Chromogranin A-Derived Bioactive Peptides, in Normal and Neoplastic Neuroendocrine Tissues.

Authors:  Noriko Kimura; Akihiro Funakoshi; Dominique Aunis; Kayoko Tateishi; Wakako Miura; Hiroshi Nagura
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

Review 6.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

Review 7.  Role and function of granin proteins in diabetes mellitus.

Authors:  Zoltan Herold; Marton Doleschall; Aniko Somogyi
Journal:  World J Diabetes       Date:  2021-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.